Emergent Contract Development & Manufacturing Services
More Content From Emergent Contract Development & Manufacturing Services
-
Humanigen & Emergent Biosolutions Announce Agreement for Phase 3 Covid-19 Therapeutic Candidate
Lenzilumab™ is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for EUA first quarter of 2021.News Releases Released on 03.04.2021
-
Emergent CDMO Capabilities - Perfecting Your Formula
Since 1998, Emergent BioSolutions has been a trusted source for solving some of the most complex and critical challenges in public health.Literature / Brochures Released on 03.04.2021
-
Delivering Peace of Mind in an Uncertain World
At Emergent BioSolutions, our mission is to protect and enhance life. In working together, we envision protecting or enhancing 1 billion lives by 2030.Literature / Brochures Released on 03.01.2021
-
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration
to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense FundingNews Releases Released on 07.08.2020
-
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing
for Johnson & Johnson’s Lead COVID-19 Vaccine CandidateNews Releases Released on 07.06.2020
-
Emergent BioSolutions to Invest $75 Million
in Canton Site and Expand Viral Vector and Gene Therapy CapabilityNews Releases Released on 06.18.2020
-
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner
for AstraZeneca’s COVID-19 Vaccine CandidateNews Releases Released on 06.11.2020
-
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program
in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and ManufacturingNews Releases Released on 06.01.2020
-
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner
for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19News Releases Released on 04.23.2020
-
Emergent BioSolutions Partners with U.S. Government for Comprehensive Response
to Expedite Development of Plasma-Derived Therapy for COVID-19News Releases Released on 04.02.2020
-
Emergent BioSolutions Signs Development and Manufacturing Agreement
with Vaxart for their Experimental Oral Vaccine Candidate for Coronavirus DiseaseNews Releases Released on 03.18.2020
-
Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates
for the Treatment and Prevention of Coronavirus DiseaseNews Releases Released on 03.11.2020
-
Emergent BioSolutions Signs Development and Manufacturing Agreement
With Novavax for Experimental Vaccine Candidate for Coronavirus DiseaseNews Releases Released on 03.10.2020
-
Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study
...News Releases Released on 02.01.2017
-
Emergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55
...News Releases Released on 01.27.2017
Related Content
